Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 3 (2006), Issue 1 (January)

1. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma.
   Am J Clin Pathol, 125(2): 209-16. [Abstract] [Full-text]
2. The association between host susceptibility factors and uveal melanoma: a meta-analysis.
   Arch Ophthalmol, 124(1): 54-60. [Abstract] [Full-text]
3. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma.
   J Clin Oncol, 24(2): 288-95. [Abstract] [Full-text]
4. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
   J Clin Oncol, 24(2): 268-73. [Abstract] [Full-text]
5. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients.
   Cancer Immunol Immunother, 55(4): 469-74. [Abstract] [Full-text]
6. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.
   Cancer Immunol Immunother, 55(4): 451-8. [Abstract] [Full-text]
7. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.
   Cancer Immunol Immunother, 55(4): 433-42. [Abstract] [Full-text]
8. Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma.
   Oncogene, 25(2): 248-59. [Abstract] [Full-text]
9. Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study.
   Arch Otolaryngol Head Neck Surg, 132(1): 73-8. [Abstract] [Full-text]
10. Regulation of local and metastatic host-mediated anti-tumour mechanisms by L-selectin and intercellular adhesion molecule-1.
    Clin Exp Immunol, 143(2): 216-27. [Abstract] [Full-text]
11. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.
    J Invest Dermatol, 126(2): 422-31. [Abstract] [Full-text]
12. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma.
    J Invest Dermatol, 126(2): 399-401. [Abstract] [Full-text]
13. Heterogeneity of T-cell clones infiltrating primary malignant melanomas.
    J Invest Dermatol, 126(2): 393-8. [Abstract] [Full-text]
14. The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor.
    Cancer Res, 66(2): 1132-8. [Abstract] [Full-text]
15. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.
    Cancer Res, 66(2): 999-1006. [Abstract] [Full-text]
16. Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts.
    Cancer Res, 66(2): 701-12. [Abstract] [Full-text]
17. Sun exposure and risk of melanoma.
    Arch Dis Child, 91(2): 131-8. [Abstract] [Full-text]
18. Population-based analysis of lymphatic mapping and sentinel lymphadenectomy utilization for intermediate thickness melanoma.
    J Surg Oncol, 93(2): 100-7; discussion 107-8. [Abstract] [Full-text]
19. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
    Oncogene, 25(4): 512-24. [Abstract] [Full-text]
20. TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis.
    Oncogene, 25(4): 650-5. [Abstract] [Full-text]
21. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study.
    J Clin Pathol, 59(2): 166-73. [Abstract] [Full-text]
22. Dermoscopy for "true" amelanotic melanoma: a clinical dermoscopic-pathologic case study.
    J Am Acad Dermatol, 54(2): 341-4. [Abstract] [Full-text]
23. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression.
    J Am Acad Dermatol, 54(2): 234-41. [Abstract] [Full-text]
24. Dermatomyositis associated with malignant melanoma--a marker of poor prognosis?
    J Am Acad Dermatol, 54(2): 221-6. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.